



## **BPH Corporate Ltd**

BPH Corporate [ASX: BPH] ASX Announcement

28 June 2010

Companies Announcements Office  
Australian Securities Exchange Limited  
10<sup>th</sup> Floor, 20 Bond Street  
SYDNEY NSW 2000

Dear Sir/Madam,

### **BPH Corporate Update on the HLS5 Tumor Suppressor Gene**

BPH Corporate Limited [ASX: BPH] is working together with the Western Australia Institute for Medical Research (WAIMR) on the tumour suppressor gene HLS5 (HLS5) which has progressed further this year.

Professor Peter Klinken stated "Our investigation into the role of HLS5 has progressed well. To further understand the role of HLS5 we are currently developing both cell lines and whole animals that have down regulated HLS5. A new lab environment is currently being set-up to enable the generation of these cell lines and will be complete in July this year with the research taking place over a few months. We want to be able to precisely define the biochemical function of HLS5."

Over the last twelve months HLS5 Senior Researcher Dr Louise Winteringham has lead the team to investigate the potential influence of HLS5 in melanoma after receiving the Scott Kirkbride Melanoma Research Centre Discovery Grant. Dr Winteringham has been working to understand if HLS5 influences the levels of proteins affecting the growth of melanoma cells and has been able to demonstrate that HLS5 associates with proteins that are able to regulate the growth and migration of melanoma cells.

The HLS5 team was also awarded a National Health and Medical Research Council (NH&MRC) Grant last year which will finish in 2012. The research conducted under this grant is continuing to look at the role of HLS5 in blood cell development, leukemia and cancer.

HLS5 has generated a large amount of data with ongoing research and continued support from WAIMR. BPH has exclusive rights to HLS5 and has an extensive patent portfolio including its use as a potential therapeutic target and underpinning its involvement in a variety of disease pathways.

The technology associated with the HLS5 is 100% owned by BPH investee company Molecular Discovery Systems Limited (MDSystems). MDSystems is a company dedicated to the Anti-Microtubule Drug Discovery Development Program along with its current High-Content Screening Facility and HLS5.

Yours sincerely,

David Breeze  
Chairman

**For more information contact:**

Mr David Breeze  
Chairman  
BPH Corporate Limited  
Tel : +61 8 9328 8366